GRI Bio launches $6.7M public offering of common stock and warrants

GRI Bio, Inc.

Offering comprises 2.6M shares, 8.1M pre-funded warrants ($0.0001/share), and 10.7M Series F warrants ($0.75/share) at $0.75 per unit.
Net proceeds expected ~$6.7M; funds working capital, product development, and general corporate purposes.
Closing anticipated December 12, 2025; H.C. Wainwright acts as placement agent with 7.0% cash fee plus warrants.
Company believes proceeds plus existing cash will fund operations into Q4 2026; 60-day lockup on further equity issuance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.